Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sarepta Therapeutics’ SEC disclosures often means sifting through pages on exon skipping science, gene therapy batch yields, and multi-year cash burn tables. If you’ve ever typed “Sarepta Therapeutics SEC filings explained simply” into a search bar, you already know the challenge. Stock Titan’s AI tackles that complexity head-on, turning dense research updates into plain-English highlights that focus on Duchenne muscular dystrophy trials, FDA milestones, and collaboration revenue streams.
Need the numbers fast? Our platform pulls every “Sarepta Therapeutics quarterly earnings report 10-Q filing” as soon as it hits EDGAR and pairs it with instant ratio analysis. Real-time alerts for “Sarepta Therapeutics Form 4 insider transactions real-time” let you see when directors buy ahead of pivotal readouts. Use AI-powered summaries to move from headline to detail across all major forms:
- Sarepta Therapeutics annual report 10-K simplified—cash runway, pipeline probability tables, and manufacturing capacity.
- Sarepta Therapeutics proxy statement executive compensation—compare leadership incentives to clinical milestones.
- Sarepta Therapeutics 8-K material events explained—FDA decisions, partnership payments, or safety updates within minutes.
The result: one page that answers the questions investors actually ask—“How did Exondys 51 sales shift this quarter?” or “What do Sarepta Therapeutics insider trading Form 4 transactions signal ahead of an FDA advisory meeting?” Whether you’re tracking “Sarepta Therapeutics executive stock transactions Form 4” or need a deep “Sarepta Therapeutics earnings report filing analysis,” our AI shows you the story behind the numbers. Start “understanding Sarepta Therapeutics SEC documents with AI” today and make faster calls on gene-therapy breakthroughs without reading hundreds of pages first.
Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.
Sarepta Therapeutics received a Schedule 13G/A from Capital International Investors disclosing a passive, beneficial holding of 524,146 common shares, equal to 0.5% of the 98,277,032 shares reported outstanding. The filing identifies Capital International Investors as a division of Capital Research and Management Company and related investment management entities and states that those entities are collectively deemed the beneficial owner of the position.
The report shows detailed control metrics: sole voting power for 523,807 shares, sole dispositive power for 524,146 shares and no shared voting or dispositive power. The filing also certifies the shares are held in the ordinary course of business and not to change or influence control of the issuer.
Sarepta Therapeutics (SRPT) Form 4 filing: Chief Technology Operations Officer Bilal Arif reported the award of 6,250 Performance Stock Units (PSUs) on 08/05/2025. The grant originates from a March 1 2024 PSU agreement; shares earned were approved by the Compensation Committee based on milestone achievement. The PSUs convert 1-for-1 into common stock and will vest on 03/01/2026, contingent on continued employment. Following the transaction, Arif directly holds 6,250 derivative securities; no shares were sold and no cash price was paid, indicating this is an incentive, not a market purchase. No changes to common-stock ownership were disclosed.
The filing signals ongoing executive retention and alignment with long-term performance targets but does not materially affect share count or near-term earnings. Investors typically view such equity awards as neutral unless unusually large relative to existing float.
Insider award: On 08/05/2025 Sarepta Therapeutics (SRPT) President of R&D and Tech Ops, Louise Rodino-Klapac, earned 6,250 Performance Stock Units (PSUs) according to a Form 4 filing. The PSUs stem from a grant dated 03/01/2024 and were unlocked after the Compensation Committee confirmed the company met specific milestones. No cash was paid (exercise price $0) and there were no share sales or disposals. All 6,250 PSUs remain un-vested and are scheduled to vest on 03/01/2026, contingent on continued employment. Following the transaction the executive beneficially owns 6,250 derivative securities directly. The filing signals milestone achievement but represents a small ownership change relative to Sarepta’s total share count, implying limited dilution or immediate market impact.
SRPT Form 4: routine tax-withholding sale
On 07/31/2025, Sarepta Therapeutics (SRPT) Chief Financial Officer Ryan Ho-Yan Wong reported the disposition of 327 common shares at $16.42 under transaction code “F,” which denotes shares surrendered to the company solely to satisfy payroll-tax obligations triggered by vesting of RSUs granted 07/30/2021. After the withholding transaction, Wong directly holds 17,328 SRPT shares; no derivative positions were listed.
The filing reflects a non-discretionary, tax-related share reduction rather than an open-market sale, and therefore carries limited signaling value regarding insider sentiment or the firm’s fundamentals.
Sarepta Therapeutics (SRPT) Form 3 records newly appointed CFO Ryan Ho-Yan Wong’s initial beneficial ownership as of 16 Jul 2025. He directly holds 17,655 common shares. The filing also lists 11 stock-option grants covering 31,031 shares with exercise prices between $67.78 and $155.99 and expirations from 2031-2035; each grant vests 25 % at the first anniversary and then monthly. No shares were bought or sold—this is a baseline disclosure required under Section 16(a). The document contains no operating, financial, or strategic updates and is unlikely to affect the investment thesis for SRPT.
FAQ
What is the current stock price of Sarepta Therapeutics (SRPT)?
What is the market cap of Sarepta Therapeutics (SRPT)?
